Company intelligence / Profile preview

Shineco Life Science Research

Beijing, China

Ownership: Private
Employees: ~119
Development stage: Other

Overview

Shineco has demonstrated rapid scaling of iPSC and phospholipid technologies, successful partnerships, and commercial launches. Clinical milestones include diagnostic reagent commercialization, and drug programs reaching Phase 2 trials and IND readiness (especially cancer and neurological indications)

Therapeutic areas: CardiovascularWomen's HealthGastroenterologyNeurologyOtherDermatologyOncology
Modalities: Induced pluripotent stem cell (iPSC) therapyExtracellular vesicle-based therapyDiagnostic reagents (medical device)Lipid nanoparticle delivery technology (for mRNA vaccines, drugs)
Industry: Biotech

Partnerships

InfiniClone (stem cell platform acquisition)Mayah Biological Holdings (proposed, cancer assets)Blockchain/cell asset tokenization collaboration

Beyond the preview

Go deeper on Shineco Life Science Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shineco Life Science Research.

Explore the full profile